Alzheimer’s disease in the EU during and after pandemic

According to the WHO, it is estimated that the crude prevalence of dementia in those aged 65+ is 8.5%, or 13.1 million (population over 65 years in the WHO European Region is 154.3 million). [Shutterstock/SewCream]

The COVID-19 pandemic has had a severe impact on health services across the EU and one public health condition that was sidelined, among others, was Alzheimer’s disease.

The World Health Organisation (WHO) has spotted serious malfunctioning in dementia diagnosis and assessment.

According to the WHO, it is estimated that the crude prevalence of dementia in those aged 65+ is 8.5%, or 13.1 million (population over 65 years in the WHO European Region is 154.3 million).

Stakeholders caution that urgent and coordinated action is needed to help EU patients and their carers cope with the challenges of Alzheimer’s disease.

Meanwhile, promising new technologies and innovative therapies in the field are constantly emerging, which patients want to take full advantage of.

Download PDF  

Subscribe to our newsletters

Subscribe